Compounds

A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein R1 is a substituent; L is a bond or a linker; A is selected from an optionally substituted- phenyl, pyridinyl and pyrazolyl; R2a and R2b are independently selected from hydrogen and a substituent; Ra and Rb i...

Full description

Saved in:
Bibliographic Details
Main Authors FRED ELUSTONDO, TILLY BINGHAM, EMMA CARSWELL, RICHARD ARMER, ANGUS MORRISON
Format Patent
LanguageEnglish
Published 21.01.2015
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:A compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof: wherein R1 is a substituent; L is a bond or a linker; A is selected from an optionally substituted- phenyl, pyridinyl and pyrazolyl; R2a and R2b are independently selected from hydrogen and a substituent; Ra and Rb independently selected from hydrogen and a substituent; m is 1, 2, 3 or 4; het is is selected from an optionally substituted- pyrrolidinylene, piperidinylene and azepanylene; R4 is selected from hydrogen and C(=Y)C(-R5)=CR6R7 wherein R5, R6 and R7 are independently selected from hydrogen and a substituent and Y is selected from oxyygen and NRc where Rc is selected from hydrogen and a substituent. These compounds are tyrosine kinase inhibitors. More specifically, the compounds are inhibitors of Brutons tyrosine kinase (BTK) and are useful for treating conditions treatable by the inhibition of BTK, for example cancer, lymphoma, leukemia and immunological diseases.
Bibliography:Application Number: GB20130012901